How Long to Hold Mounjaro Before Surgery: UK Guidance

Mounjaro (tirzepatide) is a GLP-1 and GIP receptor agonist used for type 2 diabetes management in the UK. Its effect of delaying gastric emptying raises important considerations for patients undergoing surgery, as this may increase aspiration risk during anaesthesia. UK guidance now emphasises individualised risk assessment rather than routine cessation. The decision to pause Mounjaro before surgery depends on your specific procedure, risk factors, and anaesthetist's evaluation. This article explains current UK recommendations, timeframes for pausing treatment, blood glucose management strategies, and when to safely restart Mounjaro post-operatively.

Why Mounjaro May Need to Be Paused Before Surgery

Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the management of type 2 diabetes and for chronic weight management in adults. One of its key pharmacological effects is delayed gastric emptying, which slows the movement of food from the stomach into the small intestine.^[1][4] Whilst this mechanism contributes to improved glycaemic control and satiety, it may pose risks in the perioperative setting that need individual assessment.

When undergoing surgery requiring general anaesthesia or procedural sedation, patients must typically fast to ensure the stomach is empty. This precaution reduces the risk of aspiration, a complication where stomach contents are regurgitated and inhaled into the lungs during anaesthesia. Because Mounjaro delays gastric emptying, food may remain in the stomach longer than expected, even after standard fasting periods, potentially increasing aspiration risk in some patients.

UK anaesthetic practice increasingly favours individualised risk assessment rather than universal cessation of GLP-1 receptor agonists before surgery. The Centre for Perioperative Care (CPOC) and the Association of Anaesthetists recommend discussing Mounjaro use with your anaesthetist during pre-operative assessment. This allows them to evaluate your specific risk factors, such as whether you are in the dose-escalation phase, have significant gastrointestinal symptoms, or have known gastroparesis.

This guidance applies whether you are taking Mounjaro for type 2 diabetes or for licensed weight management. Surgical teams must be informed of all medications, including Mounjaro, to allow appropriate risk assessment and fasting modifications. In some cases, particularly for higher-risk patients, your anaesthetist may recommend temporarily pausing Mounjaro before your procedure. This approach ensures your safety whilst avoiding unnecessary medication disruption for lower-risk situations.

Recommended Timeframe to Pause Mounjaro Before Surgery

The appropriate approach for Mounjaro before surgery depends on individual assessment and local hospital protocols. Tirzepatide has a half-life of approximately five days (as stated in the Mounjaro Summary of Product Characteristics, section 5.^[1][4]2), meaning it takes roughly this time for half the drug to be eliminated from the body. This pharmacokinetic profile informs perioperative planning, but recommendations vary based on individual risk factors and local policy.

Following guidance from the Centre for Perioperative Care (CPOC) and the Association of Anaesthetists, some UK hospitals and anaesthetists may recommend pausing Mounjaro for a period before elective surgery requiring general anaesthesia or deep sedation, particularly for patients with additional risk factors such as symptomatic gastroparesis or active gastrointestinal side effects. The exact timing should be determined through discussion with your anaesthetist and surgical team, following your hospital's specific protocols. Do not stop Mounjaro without first seeking advice from your surgical or anaesthetic team, and make a note of the date and time of your last dose to share with them.

For procedures involving moderate sedation or local anaesthesia only, where aspiration risk is substantially lower, continuing Mounjaro may be appropriate. This decision should be made collaboratively between you, your surgeon, and anaesthetist, taking into account your diabetes control or weight management needs, surgical complexity, and individual risk factors.

Mounjaro is administered as a once-weekly subcutaneous injection.^[1][4] If your healthcare team advises pausing treatment, they will provide specific guidance about which dose to skip. For example, if your anaesthetist recommends pausing treatment and surgery is planned for a Friday, they may advise not administering your usual injection the week before.

For emergency surgery, there is insufficient time for planned drug adjustment. In such cases, inform the emergency medical team about your Mounjaro use so they can implement appropriate precautions. Your anaesthetist may use additional risk-mitigation strategies, such as treating you as being at higher risk for retained gastric contents and adapting their approach accordingly.

Risks of Continuing Mounjaro Too Close to Surgery

Continuing Mounjaro close to surgery may increase certain perioperative risks in some patients. The primary concern relates to pulmonary aspiration, which occurs when gastric contents enter the respiratory tract during induction of anaesthesia, airway manipulation, or emergence from sedation. Case reports and observational studies have raised concerns about this risk in patients taking GLP-1 receptor agonists, and the Centre for Perioperative Care (CPOC) and the Association of Anaesthetists have highlighted it as a consideration warranting individual assessment.

Some studies examining GLP-1 receptor agonists have documented cases of retained gastric contents despite adherence to standard nil-by-mouth protocols, with gastric residue found in some patients even after prolonged fasting. This altered gastric emptying may make traditional fasting guidelines less reliable for some patients taking these medicines. The overall magnitude of aspiration risk in this context has not been precisely quantified in large UK studies, and your anaesthetist is best placed to assess your individual risk.

In some cases, anaesthetists may postpone elective surgery if they identify concerns during preoperative assessment. This is done to ensure patient safety but can cause inconvenience and anxiety. Additionally, some patients may experience nausea and vomiting during the perioperative period; gastrointestinal effects including nausea and vomiting are recognised adverse reactions of tirzepatide as listed in the Mounjaro SmPC (section 4.8), and these may potentially complicate post-anaesthetic recovery.

There is also consideration of blood glucose management if Mounjaro is paused alongside perioperative fasting. Whilst tirzepatide's glucose-dependent mechanism makes severe hypoglycaemia less likely than with insulin or sulphonylureas, the combination of medication changes, fasting, and surgical stress can create unpredictable glycaemic fluctuations.^[1][4] This is particularly relevant for patients taking additional glucose-lowering medications.

If you have concerns about the risks or benefits of continuing or pausing Mounjaro before your procedure, discuss these with your anaesthetist during your pre-operative assessment. They can provide personalised advice based on your medical history, the specific procedure, and current UK guidance.

Managing Blood Sugar During the Mounjaro Pause

If your healthcare team recommends temporarily pausing Mounjaro, you may have concerns about glycaemic control, particularly if you have type 2 diabetes. A relatively short withholding period means most patients can maintain acceptable blood sugar levels with appropriate monitoring and interim strategies.

If you are taking Mounjaro solely for weight management and do not have type 2 diabetes, you are unlikely to need intensified glucose monitoring during a brief pause unless your clinical team advises otherwise.

For patients using Mounjaro for type 2 diabetes management, discuss with your GP or diabetes team whether you need alternative glucose-lowering strategies during the brief pause. For those with well-controlled diabetes, careful monitoring may be sufficient without medication changes.

Monitoring strategies during a Mounjaro pause should be guided by your diabetes team. As a general approach, this may include:

• Increased blood glucose testing, such as checking levels at least twice daily (for example, fasting and before the evening meal), or as specifically advised by your diabetes team

• Maintaining a glucose diary to identify patterns and guide any necessary interventions

• Recognising hyperglycaemia symptoms such as increased thirst, frequent urination, fatigue, or blurred vision

The specific monitoring frequency and any glucose thresholds that should prompt you to contact your team should be agreed with your diabetes care team, as these will depend on your individual circumstances and local protocols.

Some patients may require temporary medication adjustments during the Mounjaro-free period. It is important to note that SGLT2 inhibitors (medicines such as empagliflozin, dapagliflozin, and canagliflozin) are typically stopped before surgery due to the risk of euglycaemic diabetic ketoacidosis; the Joint British Diabetes Societies (JBDS) perioperative guideline provides specific advice on timing, and your surgical team will advise you accordingly. Do not start these as temporary alternatives. Metformin handling around surgery also follows JBDS and local hospital guidance, so follow the specific instructions given by your team.

Dietary modifications can help maintain glycaemic stability, including consistent carbohydrate intake, avoiding concentrated sugars, and maintaining regular meal timing. Be aware that stress about upcoming surgery may itself affect blood glucose levels. Contact your diabetes care team or GP if you experience glucose readings outside the range your team has specified, or if you feel unwell, for guidance.

If you have complex diabetes or are concerned about managing without Mounjaro, ask for a referral to the hospital diabetes team before your procedure. They can provide a personalised perioperative diabetes management plan.

When to Restart Mounjaro After Surgery

Resuming Mounjaro after surgery requires consideration of your recovery status, oral intake tolerance, and surgical outcomes. There is no universal timeline, as the appropriate restart point varies depending on the procedure type, post-operative course, and individual factors. Generally, Mounjaro should only be restarted once you have fully recovered from anaesthesia, are tolerating normal oral intake without nausea or vomiting, and have received clearance from your surgical team.

For minor procedures with uncomplicated recovery, you may be able to resume Mounjaro once you return to your regular eating pattern. However, for major abdominal surgery, gastrointestinal procedures, or operations with prolonged recovery, a longer delay may be necessary. Your surgeon will advise when it is appropriate to restart, which might be once specific recovery milestones are achieved, such as return of normal bowel function, removal of drains, or transition to solid foods.

You should be particularly cautious about restarting Mounjaro if you experience post-operative nausea, vomiting, or delayed gastric emptying, as the medication may exacerbate these symptoms. Similarly, if your post-operative pain management includes opioid painkillers, which themselves slow gastric motility, delaying Mounjaro restart may be advisable to avoid compounding gastrointestinal side effects.

When restarting Mounjaro:

• Confirm with your surgical team that you may resume your regular medications

• Ensure you are tolerating adequate oral fluid and food intake, and that nausea and vomiting have resolved, as advised by your surgical team

• Administer your next dose according to your usual injection schedule

• Monitor for gastrointestinal side effects, which may be more pronounced after a medication break

If you have had a longer break from Mounjaro, your prescriber may advise restarting at a lower dose and gradually increasing back to your previous dose to minimise side effects. This decision should be led by your GP or prescribing clinician, in line with the Mounjaro SmPC and BNF guidance on dosing. Always contact your GP or diabetes team if uncertain about restart timing, particularly if your recovery is complicated or if blood glucose control has been challenging during the Mounjaro pause.

Discussing Your Mounjaro Plan with Your Surgical Team

Open communication with healthcare professionals is essential for safe perioperative management of Mounjaro therapy. You should proactively disclose your use of tirzepatide during all pre-operative assessments, as surgical teams may not automatically identify this medication or recognise its implications for anaesthesia. This conversation should occur as early as possible, ideally when surgery is first scheduled, to allow adequate planning time.

During your pre-operative assessment, provide comprehensive medication information, including:

• The exact medication name (Mounjaro/tirzepatide), dose, and frequency

• The date and time of your most recent injection

• The reason for use (type 2 diabetes or weight management)

• Any other glucose-lowering medications or insulin therapy

• History of gastrointestinal symptoms, gastroparesis, or previous aspiration events

The anaesthetist plays a crucial role in determining appropriate fasting protocols and whether Mounjaro should be paused. They will assess your individual risk factors and provide personalised recommendations in line with CPOC and Association of Anaesthetists guidance. You should feel empowered to ask questions about your specific plan, including whether you need to pause Mounjaro before surgery, what to expect regarding blood sugar management, and when restart is appropriate.

The diabetes care team, including GPs, practice nurses, diabetes specialist nurses, or hospital diabetes specialists, should also be involved in perioperative planning where relevant. They can provide guidance on interim glucose management and monitoring advice during any Mounjaro pause, following JBDS perioperative diabetes guidelines. Many NHS hospitals may offer dedicated perioperative diabetes support for complex cases.

Key questions to discuss with your surgical team include:

• Should I pause Mounjaro before surgery, and if so, when should I take my last dose?

• Will I need alternative diabetes medications during any pause?

• How should I monitor my blood glucose in the days before surgery?

• When can I safely restart Mounjaro after the procedure?

• What glucose levels should prompt me to contact the team before surgery?

Never hesitate to contact your surgical team or GP if you have questions or concerns about your medication management. If you experience any side effects from Mounjaro that you believe are significant, you can report them through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Collaborative planning between you, your surgical team, and diabetes or weight management specialists ensures optimal outcomes whilst minimising both surgical and glycaemic risks.

Scientific References

1. Mounjaro KwikPen 2.5mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
2. Tirzepatide for managing overweight and obesity – A practical guide to using medicines to manage overweight and obesity: prescribing, reviewing and stopping tirzepatide.
3. Obesity – Treatment.
4. Mounjaro EPAR – Product Information (INN: tirzepatide).
5. Tirzepatide | Drugs | BNF | NICE.

Frequently Asked Questions